Andere Sprachen Immatics N.V.

Aktien

A2P72S

NL0015285941

IMTX

Biotechnologie

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 16.07.2026			% 5 Tage	Veränd. 1. Jan.
9,400 ^USD	-0,74 %		-5,62 %	-10,48 %

16.07.	Moderna bewertet seine Krebstherapie - die Aktie gibt dennoch nach
15.06.	Kalender der Dividendenausschüttungen und Hauptversammlungen vom 15. bis 19. Juni 2026

Andere Sprachen

16.07.	Moderna évalue sa thérapie anticancéreuse mais le titre recule
01.06.	Immatics N.V. Announces Updated Clinical Data For IMA203CD8, IMA401, And Anzu-Cel PRAME Cell Therapies
01.06.	Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
01.06.	Immatics Presents Clinical Activity and Response Dynamics of Anzu-Cel Prame Cell Therapy At 2026 Asco Annual Meeting
31.05.	Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
31.05.	Immatics N.V. Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
31.05.	Immatics N : 2026 ASCO Immatics #11516 anzu-cel IMA203CD8 SynovialSarcoma
30.05.	Immatics presents clinical activity of Ima203cd8 Prame cell therapy in hard-to-treat gynecologic cancers
30.05.	Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
30.05.	Immatics N.V. Presents Clinical Activity Of IMA203CD8 PRAME Cell Therapy In Hard-To-Treat Gynecologic Cancers And Synovial Sarcoma
12.05.	Immatics Q1 Loss Widens, Revenue Falls
12.05.	Earnings Flash (IMTX) Immatics Posts Q1 Revenue 7.6M Euros, vs. FactSet Est of 8.5M Euros
12.05.	Earnings Flash (IMTX) Immatics Posts Q1 Net Loss 0.43 Euro a Share, vs. FactSet Est of 0.45 Euro Loss
12.05.	Immatics: Q1 Earnings Snapshot
12.05.	Immatics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2026
12.05.	Immatics Announces First Quarter 2026 Financial Results and Business Update
21.04.	Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
17.04.	Immatics N : PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
17.04.	PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
17.04.	Immatics N.V. Highlights Prame-Directed Tcr T-Cell Therapy Inducing Remission In Pediatric Nephroblastoma Patient
05.03.	Immatics N.V. Reports Earnings Results for the Full Year Ended December 31, 2025
05.03.	Immatics Swings to Fiscal 2025 Loss, Revenue Falls
05.03.	Immatics: Q4 Earnings Snapshot
05.03.	Immatics Announces Full Year 2025 Financial Results and Business Update
06.01.	Biotech Sector Poised for Growth Driven by Trial Data, Pharma Deals, BofA Says